Reviva Pharmaceuticals Holdings Inc. Warrants (25/12/2025) RVPHW 深 沪
交易中 02-02 10:33:55 美东时间
0.003
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.003
- 总市值 2.77万
- 52周最高 0.3678
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.003
- 委 比 0.00%
- 总股本 923.17万
- 历史最高 3.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.003
- 每 手 1
- 风险率 0.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reviva Pharmaceuticals Granted Nasdaq Extension to Meet Minimum Bid Price Requirement
Reviva Pharmaceuticals Granted Nasdaq Extension to Meet Minimum Bid Price Requirement Reviva Pharmaceuticals Holdings Inc. has been notified by the Nasdaq Hearings Panel that it was granted an exception to meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Stock Market.
01-26 15:37
Reviva Pharmaceuticals Publishes Data From RECOVER Phase 3 Clinical Study Of Brilaroxazine For Treatment Of Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system
01-08 21:02
Reviva Pharmaceuticals Provides Update, Written Feedback From FDA Pre-NDA Meeting, Includes A Recommendation To Conduct A Second Phase 3 Trial To Generate Additional Efficacy And Safety Data Prior To NDA Submission Of Brilaroxazine For The Treatment Of Schizophrenia; Initiation Of RECOVER-2 Registrational Trial Planned In H1 2026
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of
2025-12-23 21:12
Reviva Pharmaceuticals GAAP EPS of -$0.06
Reviva Pharmaceuticals press release (RVPH): Q3 GAAP EPS of -$0.06. As of September 30, 2025, the Company’s cash and cash equivalents totaled approximately $13.2 million compared to approximately $13....
2025-11-14 05:59
Reviva Pharmaceuticals Q3 EPS $(0.06) Beats $(0.10) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 38.78 percent. This is a 76 percent increase over losses of $(0.25) per share
2025-11-14 05:34
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
Reviva Pharmaceuticals获得欧洲专利，覆盖brilaroxazine治疗肺纤维化，包括特发性肺纤维化，全球市场已有类似专利。药物独特机制针对5-羟色胺信号失调，已获FDA孤儿药认定。临床数据显示良好耐受性，拟扩展至其他高价值适应症。
2025-11-10 13:00
HC Wainwright & Co. Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $4
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and lowers the price target from $11 to $4.
2025-10-27 18:35
Reviva Pharmaceuticals Regains Nasdaq Compliance on Market Value
Reviva Pharmaceuticals Holdings ( ($RVPH) ) just unveiled an announcement. On O...
2025-10-18 05:01
Chardan Capital Initiates Coverage On Reviva Pharmaceuticals with Buy Rating, Announces Price Target of $2
Chardan Capital analyst Rudy Li initiates coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) with a Buy rating and announces Price Target of $2.
2025-09-29 19:22
Reviva Pharmaceuticals Amends Bylaws to Ease Quorum
Reviva Pharmaceuticals Holdings ( ($RVPH) ) has issued an update. On September ...
2025-09-27 05:29
